medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2015, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2015; 13 (1)

On the Treatment of Severe Inflammatory Acne

Espinosa TM, Hernández PE, Abbas KH

Language: Spanish
References: 19
Page: 50-53
PDF size: 251.12 Kb.


ABSTRACT

Acne vulgaris may be non-inflammatory (comedogenic) and inflammatory, with the latter including severe forms. Since acne has deep consequences in self-esteem, it is necessary to treat rapidly and precisely to order to prevent or minimize residual scars. While the advent of isotretinoin has revolutionized acne treatment, this drug should be used with caution especially in cases of severe inflammation.


REFERENCES

  1. Newman M, Bowe W, Heughebaert C, Shalita A. “Therapeutic consideration for severe nodular acne”. Am J Clin Dermatol 2011; 12: 7-14.

  2. Khawaja HA, Hernández Pérez E, Meda-Alvarez TY. “Acne therapy in San Salvador”. Int J Cosmet Surg 1999; 7: 92-97.

  3. Katsambas A, Papakonstantinou A. “Acne: Systemic treatment”. Clin Dermatol 2004; 22: 412-418.

  4. Hernández-Pérez E, Henríquez A, Marroquin-Burgos R. “Isotretinoin en el acné vulgar. Experiencia en 4,000 casos”. Dermatol Rev Mex 1994; 38: 263-266.

  5. Burgos G, Hernández-Perez E. “Isotretinoína oral en el acné y sus posibles efectos adversos: ¿Cuáles son los realmente observados?” Act Terap Dermatol 2005; 28: 356-363.

  6. Hernández-Pérez E, Khawaja HA, Seijo-Cortés J. “Cystic and nodulocystic acne: Clarifying a misconception”. Cosmet Dermatol 2008; 21: 216-218.

  7. Rademaker M. “Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin”. Australas J Dermatol 2010; 51: 248-253.

  8. Charakida A, Mouser PE, Chu AC. “Safety and side effects on the acne drugs, oral isotretinoin”. Expert Opin Drug Saf 2004; 3: 119-129.

  9. Epstein ME, Amodio-Groton M, Sadick NS. “Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin”. J Am Acad Dermatol 1997 Sep; 37: 365-81; quiz 382-384.

  10. Rubin RH, Schwartz MN. “Trimethoprim-sulfamethoxazole”. N Engl J Med 1980; 303: 426-432.

  11. Tan HH. “Antibacterial therapy for acne. A guide to selection and use of systemic agents”. Am J Clin Dermatol 2003; 4: 307-314.

  12. Jen SP, Sharma R. “Trimethoprim-Sulfamethoxazole –associated rhabdomyolysis in HIV– infected patient”. Int J Std Aids 2011; 22: 411-412.

  13. Jick H. “Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patiens”. Rev Infect Dis 1982; 4: 426-428.

  14. Johnson LK, et al. “Glucocorticoid action: a mechanism involving nuclear and non-nuclear pathways”. Br J Dermatol 1982; 107 Suppl 23: 6-23.

  15. Jackson S, Gilchrist H, Nesbitt LT Jr. “Update on the dermatologic use of systemic glucocorticosteroids”. Dermatol Ther 2007; 20: 187-205.

  16. Katsambas A, Stefanaki C, Cunliffe W. “Guidelines for treating acne”. Clin Dermatol 2004; 22: 439-444.

  17. Levine RM, Rasmussen JE. “Intralesional corticosteroids in the treatment of nodulocystic acne”. Arch Dermatol 1983; 119: 480-481.

  18. Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. “Propionibacterium acnes resistance to antibiotics in acne patients”. J Am Acad Derm 1983; 8: 41-45.

  19. Levy RM, et al. “Effect of antibiotics on the oropharyngeal flora in patients with acne”. Arch Dermatol 2003; 139: 467-471.




2020     |     www.medigraphic.com